This is a plain-English translation of the academic paper above, prepared for patients, referring clinicians, and other non-specialist readers. It preserves the structure of the original paper while removing technical jargon. For the full clinical paper, follow the PubMed or DOI links.
Background
Whether the type of blood-clot prevention drug given to patients with broken hips affects how many of them survive the first 30 days, and the first year, after the injury — using national NHS data on more than a quarter of a million patients.
Rationale
Patients with hip fractures are at very high risk of dangerous blood clots in the legs and lungs, so almost every UK hospital uses some form of preventive injection. But the dose and the choice of drug vary widely between hospitals, and there has been long-standing uncertainty about which approach is genuinely safest.
Results
Hospitals using a half-dose of low molecular weight heparin (LMWH) had significantly lower in-hospital deaths, lower 30-day mortality, and lower one-year mortality than hospitals with no such policy. There was no difference in readmission for clots or for bleeding, suggesting the half-dose did not increase bleeding risk.
Implications
For someone admitted with a broken hip, the dose and choice of clot-prevention injection used in the hospital makes a real difference. Our data point to half-dose LMWH for the duration of the hospital stay as a sensible default. The study is observational and policies vary by hospital, so randomised trials are still needed to confirm the best regimen.
Source: Heidari N, Jehan S, Alazzawi S, Bynoth S, Bottle A, Loeffler M. Mortality and morbidity following hip fractures related to hospital thromboprophylaxis policy. HIP International 2012;22(1):13-21. doi:10.5301/HIP.2012.9079
Read original on PubMed → ← Back to research library